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1  Abstract： 
Purpose: Previous studies showed that epilepsy patients treated with 
levetiracetam (LEV) had a higher incidence of upper respiratory tract infections 
and experimental and clinical data suggest also an immunomodulatory actions 
of valproate (VPA). The aim of this study was, therefore, to investigate the 
influence of LEV and VPA on apoptosis and cytotoxic function of CD8+ T 
lymphocytes in vitro. 
Methods: After isolation of peripheral blood mononuclear cells (PBMCs) in 15 
healthy subjects (9 female (60%), age: 35.7±12.1 years), apoptosis and 
cytotoxic function of CD8+ T lymphocytes were measured in vitro using 
immunofluorescence labeling and flow cytometry. Drug concentrations applied 
were 5mg/L and 50mg/L for LEV and 10mg/L and100mg/L for VPA, respectively. 
Apoptosis rates of CD8+ T lymphocytes were determined after incubation of 
PBMCs with LEV or VPA for 1h or 24h. Apoptotic CD8+ T lymphocytes were 
deifiined as CD3+/CD8+/ Annexin V+/PI-  after applyingwiththe Annexin V 
Apoptosis Detection Kit® and flow cytometry. Perforin release, CD107a/b 
expression and proliferation of CD8+ T lymphocytes were measured within in the 
different groups following activation of CD8+ T lymphocytes with virus peptides, 
(which were made from cytomegalovirus, Epstein-Barr virus,  and influenza 
virus; （CEF)）. Degranulation of CD8+ T lymphocyte was indicated by perforin 
release and the increase of CD107a/b expression on the cell surface. Group 
comparisons were performed with the paired t-test. T and the significance level 
was set to p<0.05. 
Results: Both high (50mg/L) and low (5mg/L) concentrations of LEV decreased 
perforin release (LEV 50 mg/L vs controlCEF : 25.8±12.9% vs 18.2±9.7%, 
p<0.01; LEV 5mg/L vs control CEF: 24.1±13.7% vs 18.2±9.7%, p<0.01; n=15) 
and CD107a/b expression (LEV 50mg/L vs control CEF: 5.3±2.5% vs 11.5±
4.7%, p<0.01; LEV 5mg/L vs control CEF: 6.7±2.2% vs 11.5±4.7%, p<0.01; 
n=15) of CD8+ T lymphocytes after 2h of virus-peptide induced stimulation. LEV 
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had no influence on apoptosis and proliferation of CD8+ T lymphocytes (p﹥0.05). 
High concentration of VPA (100mg/L) prevented spontaneous apoptosis of CD8+ 
T lymphocytes after incubation for 24 h (VPA 100mg/L vs control: 7.8±3.4% vs 
11.5±4.2%, p<0.01, n=15), but had no effects on perforin release or CD107a/b 
expression (p﹥0.05).  
Conclusions: LEV showed a moderate attenuating effect on degranulation of 
CD8+ T lymphocytes which may contribute to the increased incidence of upper 
respiratory tract infections in LEV treated patients. Moreover, it is hypothesized 
that LEV‘s attenuating effect on perforin release adds to its anticonvulsant 
potency via reduction of inflammation in the epileptogenic zone and 
blood-brain-barrier disruption. Valproate revealed no effects onf the function of 
CD8+ T lymphocytes function but slowed apoptosis.  
 
KEY WORDS:  Levetiracetam, valproate, CD8+ T lymphocytes, apoptosis, 
perforin, CD107, degranulation, proliferation 
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Abstrakt  
Hintergrund  
Epilepsie-Patienten, die Levetiracetam einnahmen, zeigten eine höhere Rate an 
Infektionen vor allem der oberen Luftwege. Darüber hinaus wiesen 
experimentelle und klinische Daten auch auf eine immunmodulatorische 
Wirkung von Valproat hin. Der genaue Mechanismus der Beeinflussung des 
Immunsystems durch beide Antikonvulsiva ist allerdings nicht vollständig geklärt. 
Daher war es das Ziel der Arbeit, den Einfluss von Levetiracetam und Valproat 
auf die Apoptose und zytotoxische Funktion von CD8+ T- Lymphozyten in vitro 
näher zu charakterisieren.  
 
Methoden 
Nach Isolation von peripheren mononukleären Zellen im Blut bei 15 gesunden 
Probanden (9 weiblich (60%); 35, 7 ± 12,1 Jahre) wurde die Apoptoserate und 
zytotoxische Funktion von CD8+ T- Lymphozyten mittles 
durchflusszytometrische Methoden erfasst. Dabei wurde die Apoptoserate über 
die Bindung von Annexin V festgestellt. Die Funktionstestung beruhte auf dem 
Nachweis von Perforin und der Expression von CD107 nach Stimulation der 
Zellen mit viralen Proteinen (Cytomegalovirus, Epstein-Barr Virus, Influenza 
virus; CEF). Die Messungen wurden ohne und nach Inkubation mit jeweils 5 mg/l 
Levetiracetam, 50 mg/l Levetiracetam, 10 mg/l Valproat und 100 mg/l Valproat 
durchgeführt. Die Inkubationsdauer mit den jeweiligen Medikamenten wurden 
auf 1 h und 24 h festgelegt. Gruppenvergleiche wurden mit t-Tests für abhängige 
Stichproben durchgeführt bei einem Signifikanzniveau von p=0,05.  
 
Ergebnisse 
Die niedrige (5 mg/l) und die hohe (50 mg/l) Konzentration von Levetiracetam 
verminderten signifikant die Ausschüttung von Perforin (LEV 50 mg/L vs CEF 
Kontrolle : 25.,8±12,.9% vs 18,.2±9,.7%, p<0,.01; LEV 5mg/L vs KontrolleCEF: 
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24,.1±13,.7% vs 18,.2±9,.7%, p<0,.01; n=15) und CD107 Expression auf CD8+ 
T- Lymphozyten (LEV 50mg/L vs KontrolleCEF: 5,.3±2,.5% vs 11,.5±4,.7%, 
p<0,.01; LEV 5mg/L vs KontrolleCEF: 6,.7±2,.2% vs 11,.5±4,.7%, p<0,.01; 
n=15) nach Stimulation mit Viruspeptiden (p < 0,01). Levetiracetam zeigte 
keinen signifikanten Einfluss auf die Apoptoserate von CD8+ T- Lymphozyten. 
Die hohe Konzentration von Valproat (100 mg/l) zeigte eine signifikante 
Verminderung der Apoptoserate von CD8+ T- Lymphozyten nach einer 
Inkubationsdauer von 24 h (VPA 100mg/L vs Kontrollecontrol: 7,.8±3,.4% vs 
11,.5±4,.2%, p<0,.01, n=15), hatte aber keinen Effekt auf die Ausschüttung von 
Perforin oder CD107 Expression (p>0,05).  
 
Schlussfolgerung  
Levetiracetam bewirkte eine moderate Verminderung der Degranulation von 
CD8+ T- Lymphozyten, was ein möglicher Pathomechanismus für die klinisch 
bemerkte, erhöhte Infektionsrate bei mit Levetiracetam behandelnden 
Epilepsiepatienten darstellen könnte. Darüber hinaus führen die Ergebnisse zu 
der Hypothese, dass auch ein Teil der antikonvulsiven Wirkung von 
Levetiracetam durch die aufgezeigten immunmodulatorischen Effekte bedingt 
sein könnte, im Sinne einer Reduktion von Entzündung in der epileptogenen 
Zone und einer Stabilisierung der Bluthirnschranke. Valproat hatte keinen 
Einfluss auf die Funktion von CD8+ T- Lymphozyten, aber verlangsamte die 
Apoptoserate. 
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2  Abbreviations  
AED  Antiepileptic drug 
APC  Allophycocyanin 
AcOH     Acetic acid  
BBB  Blood-brain-barrier 
CFSE  Carboxyl fluorescein succinimidyl ester 
CNS  Central nervous system 
CTM  Cell culture medium 
EEG  Electroencephalography 
EMEA  European Agency for Evaluation of Medicinal Products 
FITC  Fluorescein isothiocyanate 
GABA  gamma-aminobutyric acid 
GTCS  Generalized tonic–clonic seizures 
HDAC  Histone deacetylase 
IFN     Interferon 
IGE    Idiopathic generalized epilepsies 
IL-2    Interleukin-2 
ILAE  International League Against Epilepsy 
JME  Juvenile myoclonic epilepsy 
LEV  Levetiracetam 
MEG  Magnetoencephalography 
MHC  Major histocompatibility complex 
MRI  Magnetic resonance imaging 
NK     Natural killer 
PBMCs  Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
 １０ 
PE     Phycoerythrin 
PerCP  Peridinin chlorophyll protein 
PI     Propidium iodide 
PS     Phosphatidylserine 
SV2A  Synaptic vesicle protein 2A 
TNF  Tumour necrosis factor 
USFDA  United States Food and Drug Administration 
VPA  Valproate 
WHO  World Health Organization 
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3  Introduction and discussion 
3.1 Epilepsy and its treatment 
Epilepsy is estimated by the World Health Organization to affect 0.8% of 
the world‘s population (WHO, 2005). Although epilepsy is a relatively 
common neurological disorder, there is a debate within the epilepsy 
community regarding the precise definition of epilepsy. In 2006, the 
International League Against Epilepsy (ILAE) provided a definition of 
‗seizure‘ and ‗epilepsy‘. A seizure was defined as ‘a transient occurrence of 
signs and/or symptoms due to abnormal excessive or synchronous 
neuronal activity in the brain‘ (Fisher et al., 2005). Epilepsy was defined 
as ‘a disorder of the brain characterized by an enduring predisposition to 
generate epileptic seizures, and by the neurobiologic, cognitive, 
psychological, and social consequences of this condition. The definition of 
epilepsy requires the occurrence of at least one epileptic seizure‘ (Fisher et 
al., 2005). The main counterarguments about the proposed definition for 
‗epilepsy‘ are that: (1) this definition requires the occurrence of at least one 
epileptic seizure, however, many persons with a central nervous system 
(CNS) lesion may never have another seizure, and diagnosing and treating 
everyone using the proposed definition may lead to overtreatment and 
unnecessarily labeling many people as having epilepsy (Beghi et al., 2005; 
Leppik and Birnbaum, 2010); (2) the failure to clarify the concept of 
‗enduring‘ is another problem with the proposed definition, and it is very 
difficult to define or make operational this term (Beghi et al., 2005). In spite 
of that the the precise definition for ‗epilepsy‘ has often been debated, the 
consensus on the matter also exists. For example, it is generally accepted 
that epilepsy is a ‗symptom‘ or ‗condition‘ rather a ‗disease‘, which has a 
tendency to have recurrent seizures. Moreover, the most widely used 
classification of ‗seizure‘ and ‗epilepsy‘ is still that proposed by ILAE in 
1981 and 1989 (Commission 1981, 1989). Seizures and epilepsies are 
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differentiated in focal and generalized seizures/epilepsies. Partial seizures 
are ones in which the first clinical and electrographic changes suggest 
initial activation limited to part of one cerebral hemisphere. Generalized 
seizures are those in which the first clinical changes indicate initial 
involvement of both hemispheres. In addition, the diagnosis of an epileptic 
syndrome in addition to a classification of seizures is also important for the 
optimal individual selection of anticonvulsant drugs. An epileptic syndrome 
is defined as a complex of signs with characteristic seizure types, onset of 
first manifestation, familial disposition and clinical findings from 
neurological examination, magnetic resonance imaging (MRI) and 
electroencephalography (EEG) or magnetoencephalography (MEG) 
(Stefan and Feuerstein, 2007). 
Pharmacologic therapy represents the first line of treatment of epilepsy and 
is effective in most patients except those develop intractable seizures. The 
history of effective drug treatment began with the introduction of bromides 
in 1857 based on later-discredited theories of the cause of epilepsy 
(Shorvon and Sander, 1996). Until now, more than 20 AEDs have been 
approved in Europe, United States and elsewhere. The first generation of 
AEDs were often detected by chance, for example, valproate (described 
below). Since 1990s, the second generation of AEDs was introduced for 
clinical use (felbamate, vigabatrin [VBG], LEV and so on). Their 
antiepileptic effects were often verified by a series of strict, multicenter, 
randomized, controlled clinical studies, which are often absent for the first 
generation of AEDs. It still remains unclear for the antiepileptic mechanism 
of some AEDs. At the molecular level, the majority of AEDs are thought to 
modify excitatory and inhibitory neurotransmission through effects on 
voltage-gated ion channels (e.g., sodium and calcium), 
gamma-aminobutyric acid (GABA)(A) receptors and glutamate-mediated 
excitatory neurotransmission, respectively (White et al., 2007). But, many 
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second generation of AEDs often have special target points, for example, 
the synaptic vesicle protein 2A (SV2A) is probably the antiepileptic target 
point for LEV. The choice of AED needs to be individualized, mainly on the 
basis of the patient profile, including seizure or epilepsy type (partial or 
generalized), tolerability, safety, ease of use and pharmacokinetics 
(Schmidt, 2009). From a clinical perspective, the ideal AED does not 
require monitoring of plasma concentrations, is metabolically inert and is 
not involved in adverse drug interactions, and can be conveniently given 
once or twice a day (Patsalos and Perucca, 2003). Based on this viewpoint, 
the second generation of AEDs are often more ideal than the first 
generation of AEDs because most of new AEDs are less enzyme inducing 
and are not metabolized by the oxidative cytochrome p450 system. But, 
adverse side effects can not be absolutely avoided for new AEDs. Insight in 
these mechanisms of adverse side effects is essential for right usage of 
new AEDs and even facilitates elucidation of their antiepileptic mechanism. 
3.2 Aim of the study 
An increasing body of literature suggests that inflammation and immune 
processes play an important role in focal epilepsy (Vezzani et al., 2002; 
Heils et al., 2000; Balosso et al., 2008). Inflammatory mediators expressed 
from glia cells and neurons in the epileptic zone contribute to the notion that 
these processes may be essential to epilepto- and ictogenesis rather than a 
mere epiphenomenon (Rizzi et al., 2003; Ravizza et al., 2008 ).  
Levetiracetam (LEV) is a new generation antiepileptic drug (AED) whose 
efficacy and tolerability in epilepsy treatment is well recognized (Vigevano, 
2005; De Smedt et al., 2007). Several clinical trials reported a clear 
anticonvulsant effect of LEV but also an increased incidence of common 
cold, pharyngitis and rhinitis in LEV-treated patients (Table 1, 
Ben-Menachen et al. 2000; Cereghino et al. 2000; Betts et al. 2000; 
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Shorvon et al. 2000; Peltola et al. 2009). The reason for this finding is 
unknown. It was reported that white blood cell and neutrophil counts were 
in the normal range in LEV and placebo treated patients who developed 
infections (French et al., 2001). Recently, we found in a pilot study that 
CD8+ T lymphocytes counts tended to decrease in the blood of LEV-treated 
patients (Nowak et al, 2010). The primary role of CD8+ T lymphocytes is to 
protect against viral infections by lysing infected cells via 
degranulation-dependent perforin release, which can be measured by 
increased expression of surface CD107a and CD107b (Betts et al., 2004), 
and secretion of soluble factors, such as interferon-γ  and tumor necrosis 
factor-α ) (Jin et al., 1999; Schmitz et al., 1999; Haridas  et al., 2003; van 
Lier et al., 2003 ; Mosley  et al., 2005; Kaech et al., 2007). 
Treatment with other AED including valproate (VPA) was not found to be 
associated with a higher infection rate (Ben-Menachem et al., 1996; 
Tassinari et al., 1996; Marson et al., 2007a; Marson et al., 2007b). However, 
VPA is a potent histone deacetylase (HDAC) inhibitor (Kawagoe et al., 2002; 
Kuendgen et al., 2006; Bokelmann and Mahlknecht, 2008), and histone 
modifications play a role in the regulation of the effector functions of 
memory CD8+ T cells (Araki et al., 2008). Moreover, VPA can induce 
apoptosis in various leukemia cells in vivo and in vitro (Kawagoe et al., 
2002; Kuendgen et al., 2006; Bokelmann and Mahlknecht, 2008). Valproate 
influenced postictal blood levels of TNFα and interleukin (IL)-1β as well as 
decreased CD4+ T cell counts (Bauer et al., 2008; Bauer et al., 2009). 
Therefore, we investigated the influence of LEV or VPA on proliferation, 
apoptosis, CD107 expression or perforin release of CD8+ T lymphocytes in 
vitro in order to better understand their pharmacological effects and 
adverse events. 
 １５ 
Table 1: Incidence of infection in several large, well-controlled clinical studies of LEV 
 
No. Study Therapy type Treatment Cases  
Incidence  of 
infection
#
 % 
1 
Ben-Menachen et al. 
2000 
Add-on, then 
Monotherapy 
Placebo 
LEV 3000mg/day 
105 
181 
3.8 
7.2 
2 Cereghino et al. 2000 Add-on therapy 
Placebo 
LEV 1000mg/day 
LEV 3000mg/day 
95 
98 
101 
12.6 
27.6 
26.7 
3 Betts et al. 2000 Add-on therapy 
Placebo 
LEV 2000mg/day 
LEV 4000mg/day 
39 
42 
38 
7.7 
2.4 
15.8 
4 Shorvon et al. 2000 Add-on therapy 
Placebo 
LEV 1000mg/day 
LEV 2000mg/day 
112 
106 
106 
6.3 
9.4 
6.6 
5 Peltola et al. 2009 Add-on therapy 
Placebo 
LEV 1000mg/day 
79 
77 
3.8 
7.8 
6 
Pooled analyses 
(including study No. 1-3 
and a crossover trial 
N051 containing study 
No. 4) by Harden 2001 
and French et al. 2001  
Monotherapy 
and add-on 
therapy 
Placebo 
 
1000-4000mg/day 
439 
 
769 
7.5 
 
13.4 
No.1-6 
Monotherapy 
and add-on 
therapy 
Placebo 
1000-2000mg/day 
3000-4000mg/day 
518 
526 
320 
6.9 
11.4* 
14.4** 
#: primarily common cold; 
*: p<0.05, comparing with placebo group, χ2 test; 
**: p<0.01, comparing with placebo group, χ
2
 test 
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3.3 Levetiracetam  
Levetiracetam (LEV) (Keppra™, ucb L059, 
[S]-alpha-ethyl-2-oxo-1-pyrrolidine acetamide, UCB S.A. Pharma  Sector, 
Braine-l‘Alleud, Belgium) is a new generation AED. As an S-enantiomer 
pyrrolidone derivative,  its structure is unrelated to other AEDs, with an 
empirical formula of C8H14N2O2 and a molecular weight of 170.21 (Fig. 1) 
(Cereghino et al., 2000;. De Smedt et al., 2007). Moreover, it is also unique 
from its predecessors both in mechanism and lack of interaction with other 
drugs (Patsalos, 2000; Bromfield, 2004; French et al., 2004a; French et al., 
2004b).  
 
Figure 1. Chemical structures of levetiracetam (LEV) 
 
3.3.1 Pharmacokinetic and pharmacodynamic 
LEV has a favorable pharmacokinetic profile with excellent oral absorption, 
minimal protein binding, lack of hepatic metabolism, and renal excretion. 
LEV is rapidly and almost completely (>95%) absorbed after oral 
administration. (Edwards et al. 2004; Patsalos 2004). When taking the drug 
on an empty stomach, its peak plasma concentration is reached within 1 
hour after dosing irrespective of the dose (Radtke, 2001). LEV has linear 
pharmacokinetics in the therapeutic range of 500–5000 mg (Patsalos 2004). 
The plasma half-life of oral levetiracetam in adults is 7 ±1 hour. (Radtke, 
2001). LEV is insignificantly protein-bound (<10%), and is mainly excreted 
unchanged in the urine; about 24% is excreted in the urine as its carboxylic 
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derivative, UCB L057, via cytochrome P450-independent enzymatic 
hydrolysis (Coupez et al. 2003). In addition, LEV does not increase the 
activity of the hepatic cytochrome P450 enzyme system. (Coupez et al. 
2003; Patsalos 2004). 
LEV is unlikely to interact with other drugs, because it has a low protein 
binding (<10%) and is not cytochrome P450-dependent (Patsalos, 2000; 
Pellock et al., 2001). Meta-analysis revealed that LEV does not affect the 
concentrations of carbamazepine, clobazam, clonazepam, diazepam, 
gabapentin, lamotrigine, phenytoin, phenobarbital primidone, VPA, 
vigabatrin, and ethosuximide (De Smedt et al., 2007). Conversely, 
phenytoin, mesuximide, carbamazepine and oxcarbazepine have been 
shown to lower LEV concentrations (De Smedt et al., 2007). 
3.3.2 Mechanism of action 
LEV is different in its mechanism of action from that of classic AEDs and 
unrelated to known mechanisms of neurotransmission. In studies on 
experimental animals, LEV has no anticonvulsant effect on traditional 
seizure models—maximal electroshock- and pentylenetetrazol-induced 
seizures in mice and rats (Gower et al., 1992; Löscher et al., 1993; 
Klitgaard et al., 1998 ). Conversely, potent antiepileptic activity is identified 
in the audiogenic seizureprone mouse model  (Gower et al., 1992). 
Moreover, LEV is also particularly effective in the treatment of absences 
and tonic seizures in ‗spontaneously epileptic rats‘ (Cai et al., 2002). 
Significant inhibition of pentylenetetrazol kindling in mice and amygdala 
kindling in rats, which are chronic kindling model, has also been found 
(Gower et al., 1992; Löscher et al., 1998 ).  
The exact anticonvulsant mechanism of LEV still remains unknown. It does 
not bind to receptors associated with excitatory or inhibitory 
neurotransmitters, nor does it act on sodium or calcium channel functions 
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or interfere with γ-aminobutyric acid (GABA) transaminase or glutamic acid 
decarboxylase (Vigevano, 2005). SV2A was identified as the binding site of 
LEV in the brain (Lynch et al., 2004). There is a strong correlation between 
the affinity of LEV-related compound for SV2A and its ability to protect 
against seizures in an audiogenic mouse animal model of epilepsy (Lynch 
et al., 2004). Proepileptic phenotype of SV2A-deficient mice is associated 
with reduced anticonvulsant efficacy of LEV and even partial SV2A 
deficiency may lead to increased seizure vulnerability and accelerated 
epileptogenesis (Kaminski et al., 2009). SV2A is associated with synaptic 
vesicle fusion, exocytosis, and neurotransmitter release (Crowder et al., 
1999). So, the specific effect of LEV binding to SV2A appears to be a 
reduction in the rate of vesicle release (Yang et al 2007).  
3.3.3 Indication and usage  
LEV received United States Food and Drug Administration (USFDA) 
approval in late 1999 as an adjunctive treatment for partial seizures in 
adults (Harden, 2001). In 2000, LEV monotherapy (1500mg twice daily) 
was reported to be effective and well tolerated in patients with refractory 
partial seizures (Ben-Menachem and  Falter, 2000). In recent years, 
double blind studies demonstrated the efficacy of LEV, in comparison to 
placebo, as an adjunctive treatment in patients with idiopathic generalized 
epilepsies (IGE) and generalized tonic-clonic seizures (GTCS) and in 
patients with refractory myoclonic seizures (Berkovic et al. 2007; Noachtar 
et al., 2008). As of January 2007, European Agency for Evaluation of 
Medicinal Products (EMEA) guidelines state that LEV is indicated: 1) As 
monotherapy in the treatment of partial-onset seizures with or without 
secondary generalization in patients from 16 years of age with newly 
diagnosed epilepsy, 2) As adjunctive therapy in the treatment of 
partial-onset seizures with or without secondary generalization in adults 
and children from four years of age with epilepsy, 3) As adjunctive therapy 
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in the treatment ofmyoclonic seizures in adults and adolescents from 12 
years of age with juvenile myoclonic epilepsy (JME), and 4) As adjunctive 
therapy in the treatment of primary generalized tonic–clonic seizures in 
adults and adolescents from 12 years of age with IGE (De Smedt et al., 
2007). 
3.3.4 Adverse events  
Generally speaking, LEV is considered a well-tolerated AED. For 
LEV-treatment, the most frequent adverse events are somnolence, 
asthenia, infection and dizziness (Harden, 2001). Several clinical trials 
reported an increased incidence of infection (primarily common cold), 
pharyngitis and rhinitis in LEV-treated patients (Ben-Menachen et al. 2000; 
Cereghino et al. 2000; Betts et al. 2000; Shorvon et al. 2000; Harden 2001; 
French et al. 2001). The pooled analyses including these studies verified 
that LEV-treated patients were more prone to infection than the 
placebo-treated groups (Harden 2001; French et al. 2001,  Table 1). 
Previous researchers have paid little attention to the reasons for raised 
infection incidence by LEV-treatment. It was reported that white blood cell 
and neutrophil counts were in the normal range for LEV and placebo 
patients who developed an infection (French et al., 2001), so, the liability to 
infection was once thought as the result of an enhanced socialization due 
to seizure improvement or confusing terminology of ‗infection‘ in different 
investigations (Cramer et al., 2000; French et al., 2001). But, this 
explanation is contradicted by the fact that many old or new generation 
AEDs, for example VPA and topiramate, do not increase the infection 
incidence following with the seizure improvement (Ben-Menachem et al., 
1996; Tassinari et al., 1996; Marson et al., 2007a; Marson et al., 2007b). T 
Therefore, we proposed the alternative hypothesis that LEV maybe has 
some influence on immune system.  
3.4 Valproate  
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VPA was first synthesized by an American chemist (Burton) in 1882 (Fig. 2) 
(Burton, 1882). But until 1962, its anti-convulsant properties were 
serendipitously discovered by French researchers (Eymard et al), when it 
was being used as a solvent for other compounds (khelline derivatives) 
whose protective effects against pentylenetetrazol-induced seizures were 
being investigated (Chapman et al., 1982; Johannessen and Johannessen, 
2003). Then, VPA was authorized for use as an AED in 1967 in France 
(marketed as ‗Depakine‘), in 1973 in Great Britain and in 1978 in the USA 
(Chapman et al., 1982; Lo s¨cher, 2002). Today , VPA is a first-line and the 
most commonly used AED, with a very broad spectrum of activity against 
both generalized and partial seizures in adults and children (Davis et al, 
1994; Chadwick , 1994; Lo s¨cher, 2002; Perucca, 2002). 
 
Figure 2. Chemical structures of Valproate (VPA) 
Although VPA is a classical old generation AED, its anticonvulsant 
mechanism still remains unclear and might involve several mechanisms, 
including enhancement of GABA inhibitory effects in CNS, modulating 
bioactivity of enzymes related to the metabolic pathways of GABA and 
cerebral metabolism, attenuation of N-methyl-D-aspartate 
receptor-mediated excitation, and its interactions with sodium, calcium and 
potassium channels (Johannessen, 2000; Isoherranen et al., 2003). VPA is 
rapidly and nearly totally eliminated by hepatic metabolism involving in 
microsomal oxidation and glucuronidation (CYP2C9, CYP2C19 and 
CYP2A6) (Peterson and Naunton, 2005). Its half-life is 16–17 h (Chapman 
et al, 1982). Besides, its pharmacokinetics are also characterized by 
dose-limited absorption and non-linear plasma protein binding (DeVane, 
2003). The main side effects of VPA are idiosyncratic hepatic toxicity, 
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thrombocytopenia and teratogenicity (Peterson and Naunton, 2005). Side 
effects are more frequent at higher doses, particularly serious side effects 
such as hepatotoxicity and thrombocytopenia (Ferrendelli, 2001).The risk 
for fatal hepatotoxicity is greater in very young children (Ferrendelli, 2001). 
VPA was involved in the current study due to three reasons:  
1) Treatment with VPA was not found to be associated with a higher 
infection rate (Ben-Menachem et al., 1996; Tassinari et al., 1996; 
Marson et al., 2007a; Marson et al., 2007b);  
2) VPA has also been described as a potent HDAC inhibitor (Kawagoe et 
al., 2002; Kuendgen et al., 2006; Bokelmann and Mahlknecht, 2008). 
HDAC inhibitors promote histone acetylation (Melnick and Licht, 2002; 
Johnstone and Licht, 2003). Acetylation of histone correlates with a 
global architectural alteration from hetero- to transcriptionally active 
euchromatin, which menas chromatin relaxation, uncoiling and allowing 
for gene transcription (Melnick and Licht, 2002; Johnstone and Licht, 
2003; Lin et al, 2006). Interestingly, HDAC inhibitors also display 
pleiotropic antitumor effects including cell cycle arrest, inhibition of 
angiogenesis, induction of apoptosis and of differentiation (Bouzar et al., 
2009). It has been reported that VPA can induce apoptosis of various 
leukemia cells in vivo and in vitro (Kawagoe et al., 2002; Kuendgen et 
al., 2006; Bokelmann and Mahlknecht, 2008). Moreover, histone 
acetylation plays a role in the regulation of the effector function of 
memory CD8+ T lymphocytes through facilitating rapid and robust 
transcriptional response (Araki et al., 2008). 
3) VPA influenced postictal blood levels of TNFα and interleukin (IL)-1β as 
well as decreased CD4+ T cell counts (Bauer et al., 2008; Bauer et al., 
2009). 
3.5 CD8+ T lymphocytes and its antivirus function 
Both innate immunity and adaptive immunity contributes to resistance to 
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virus infection. Innate immunity generally plays a role immediately after 
infection to limit the spread of the pathogen and initiate efficient 
development of an adaptive immune response (Bertoletti and Gehring, 
2007). Innate immune responses during the early phases of viral infections 
are mainly characterized by production of type 1 interferons (Alexopoulou 
et al., 2001; Heil et al., 2004), activation of natural killer (NK) (Lanier, 2008), 
induction of dendritic cell maturation (Dalod et al. 2003), modulation of the 
quantity of major histocompatibility complex (MHC)-class I molecules on 
the surface of infected cells (Moretta et al., 2005) and priming of CD8+ T 
lymphocytes responses (Tough et al., 1996). 
Despite innate immunity being a first line of defence against virus infection, 
adaptive immunity, mainly for cell-mediated immune response, is still 
crucial for controlling virus infection (Mosley et al., 2005; Thimme et al., 
2003; Lukacher and Wilson, 1998). The phenotype of CD8+ T lymphocytes 
was established in 1975 (Masopust et al. 2007). It has been demonstrated 
that CD8+ T lymphocytes are pivotal in the resolution of many acute viral 
infections (Jin et al., 1999; Schmitz et al., 1999; Haridas  et al., 2003; 
Mosley  et al., 2005 ). For example, CD4+ or CD8+ T lymphocytes deletion 
experiments performed in hepatitis B virus infected chimpanzees showed 
that CD8+ T lymphocytes were the main cellular subset responsible for viral 
clearance (Thimme et al., 2003). It was also reported that CD8+ T 
lymphocytes are critical for the clearance of acute polyomavirus infection in 
the mouse model (Lukacher and Wilson, 1998). Interestingly, independent 
of T cell receptor ligation, CD8+ T lymphocytes can mount a response 
against pathogens by secreting cytokines, indicating that CD8+ T 
lymphocytes can also play a role in innate immunity (Berg and Forman, 
2006). Morover, there is a growing belief that establishing effector memory 
CD8+ T lymphocytes at common portals of pathogen entry, such as 
mucosal tissues, may be critical for limiting the initial infectious burst of 
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certain agents (Masopust et al. 2007). Recently, we found in a pilot study 
that the counts of CD8+ T lymphocytes decreased in the blood of 
LEV-treated patients with epilepsy (Nowak et al, 2010). Due to the key role 
of CD8+ T lymphocytes in antiviral immunity, we decided to further 
investigate whether LEV or VPA can change the survival and cytotoxic 
function of CD8+ T lymphocytes. 
CD8+ T lymphocytes protect against viral infections by lysing infected cells 
via degranulation-dependent perforin release and secretion of soluble 
factors, such as interferon-γ  and tumor necrosis factor-α  (Walker et al., 
1986; Walker et al., 1987; Trapani and Smyth, 2002; van Lier et al., 2003; 
Kaech et al., 2007). Clonal proliferation of virus-specific CD8+ T 
lymphocytes can further amplify their cytotoxic effects (Koup et al., 1994; 
Kostense et al., 2001; Kostense et al., 2002). 
Degranulation-dependent lysis is the critical cytotoxic mechanism and 
correlates directly with cytotoxicity of CD8+ T lymphocytes (Betts et al, 
2003). After a killer cell recognizes its target, the cytotoxic granules move to 
the immunological synapse, where their membrane fuses with the killer cell 
plasma membrane, then they release their contents into target cells (Hayes 
et al. 1989; Stinchcombe et al, 2001). The cytotoxic granules of CD8+ T 
lymphocytes are membrane-bound secretory lysosomes that contain a 
dense core composed of various proteins, including perforin and 
granzymes (Peters et al., 1991). The core is surrounded by a lipid bilayer 
containing lysosomal associated membrane glycoproteins (LAMPs), 
including CD107a (LAMP-1), CD107b (LAMP-2), and others (Peters et al., 
1991). Degranulation can cause positive expression of CD107a/b on the 
cell surface for a brief period of time before those proteins are internalized 
(Fukuda, 1991). Perforin is a 70 kDa protein and the key player in the 
cytotoxic granule of CD8+ T lymphocytes (Russell and Ley, 2002; 
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Lieberman, 2003). The major function of perforin is to form pores about 16 
nm in diameter in the plasma membrane of target cells, facilitating the entry 
of granzyme which leads to DNA fragmentation (Young et al., 1986; Liu et 
al., 1995; Kagi et al., 1995a,b). Mice lacking perforin expression were 
unable to clear infection with the non-cytopathic lymphocytic 
choriomeningitis virus (Kagi et al., 1994; Kagi et al, 1995b). The lysis of 
HIV-infected cells by CD8+ T lymphocytes occurs primarily through granule 
exocytosis, which requires perforin to facilitate the entry of 
apoptosis-inducing serine protease granzymes into the cytosol of infected 
target cells (Shankar et al., 1999). Both perforin release and CD107a/b 
expression on the cell surface may be used for assessing degranulation of 
CD8+ T lymphocytes (Weren et al., 2004; Betts et al., 2004).  
3.6 Summary 
In the current study, we investigated the influence of LEV or VPA on 
proliferation, apoptosis, CD107 expression or perforin release of CD8+ T 
lymphocytes in vitro in order to better understand their pharmacological 
effects and adverse events. CD8+ T lymphocytes were activated with virus 
peptides under the presence or absence of LEV or VPA. Apoptosis, perforin 
release, the increase of CD107a/b expression on cell surface and 
proliferation of CD8+ T lymphocytes were observed with 
immunofluorescence labeling and flow cytometry. Perforin release and the 
increase of CD107a/b expression on cell surface were taken as the main 
markers of cytotoxicity of virus-peptides-specific CD8+ T lymphocytes.  
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4  Materials and Methods 
4.1 Study population 
Fifteen healthy adult volunteers recruited from the staff of Department of 
Neurology, University of Marburg (9 female, age: range 18-60 years, 35.7±
12.1 years) were included in the study. They fulfilled following inclusion 
criteria:  
1) no infectious diseases within the last 3 months;  
2) no neurological diseases; 
3) no autoimmune diseases;  
4) no malignant tumors; 
5) no hematological diseases;  
6) no trauma within the last month;  
7) no operations within the last month; 
8) no immunomodulatory treatment during the last six months;  
9) no hepatic or renal insufficiency;  
10) no severe psychiatric diseases;  
11) no pregnancy;  
12) informed consent must be obtained from the volunteer. 
The study was approved by the local ethics committee. 
4.2 Antibodies, reagents and peptides 
The following antibodies, reagents and peptides were purchased from BD 
Biosciences (San Jose, California, USA): Allophycocyanin (APC) 
-conjugated to mouse-anti-human CD3 (CD3-APC), peridinin chlorophyll 
protein (PerCP)-conjugated to mouse-anti-human CD8 (CD8- PerCP), 
phycoerythrin (PE)-conjugated to mouse-anti-human perforin (cloneδ G9) 
(perforin-PE) and IgG isotype control antibody (IgG-PE isotype control), 
fluorescein isothiocyanate (FITC)-conjugated to mouse-anti-human 
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CD107a/b (CD107a/b-FITC), Perm/Wash Buffer, Cytofix/CytopermTM 
solution and BD GolgiStop (containing monensin). Ficoll-Biocoll separating 
solution and phosphate buffered saline (PBS) were purchased from 
Biochrom AG (Berlin, Germany). Annexin V-FITC apoptosis detection kit 
(containing Annexin V-FITC and propidium iodide (PI)) was purchased from 
BioVision (Mountain View, California, USA). Carboxyl fluorescein 
succinimidyl ester (CFSE) was purchased from Invitrogen (Eugene, Oregon, 
USA). Recombinant human interleukin-2 (rhIL-2) was purchased from 
ProSpec (Rehovot, Israel). Pooled human AB serum was purchased from 
3H Biomedical AB (Uppsala, Sweden). Trypan blue solution (0.4%) was 
purchased from GIBCO (Paisley, Scotland, UK). RPMI 1640 (containing 
20mM HEPES and glutamine) and 1% penicillin-streptomycin were 
purchased from Sigma (Steinheim, Germany). CTL-CEF-Class I peptide 
pool ―Plus‖ (CEF peptide) was purchased from Cell Technolgy Ltd 
(Cleveland, Ohio, USA).   
4.3 Antiepileptic drugs 
Levetiracetam (Keppra®, UCB Pharma S.A., Brussels, Belgium) and VPA 
(sodium valproate, Ergenyl® vial, Sanofi Aventis, Frankfurt, Germany) were 
dissolved in sterile physiological saline to produce fresh solutions as 
required. When treating cells, the drugs were further diluted in the culture 
medium to the final concentrations of 5mg/ or 50mg/L for LEV (serum 
reference range in adults for drug fasting levels: 12–46 mg/L) and 10mg/ 
or 100mg/L for VPA (serum reference range in adults for drug fasting levels: 
50mg/–100mg/L) (Patsalos et al., 2008). 
4.3.1 VPA dilution  
(1) was added 4 ml H2O  100 mg/ml (dilution 1) 
(2) took 500 µl of dilution 1 and was added 9.5 ml H2O  5 mg/ml  
(dilution 2) 
(3) took 1 ml of dilution 2 and was added 9 ml H2O  500 µg/ml    
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(dilution 3) 
4.3.2 LEV dilution  
(1) LEV stock solution: Keppra® contains 5 ml solution of 100 mg/ml LEV 
per bottle (dilution 1).  
(2) taken 250 µl of dilution 1 and was added 9.75 ml H2O  2.5 mg/ml 
(dilution 2) 
(3) taken 1 ml of dilution 2 and was added 9 ml H2O  250 µg/ml   
(dilution 3) 
When treating the cells, the drugs were further diluted in the culture 
medium to the final concentrations of 5 or 50 mg/L for LEV (reference range 
in adults, drug fasting levels: 12-46 mg/L) and 10 or 100 mg/L for VPA 
(reference range in adults, drug fasting levels: 50-100 mg/L) (Patsalos et al., 
2008). 
4.4 Apoptosis evaluation 
4.4.1 Isolation of peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMCs) were isolated with 
Ficoll-Biocoll Separating Solution by density gradient centrifugation 
(1500rpm, 20 oC, 30 min, without brake) of heparinized blood  (10 ml) 
obtained by venepuncture of the heathy volunteers. The viability of PBMCs 
obtained was always >95%, as determined by 0.4% trypan blue staining. 
After double washing in cold PBS, the PBMCs were cultured with RPMI 
1640 supplemented with 10% heat-inactivated pooled human AB serum 
and 1% penicillin-streptomycin. 
PBMCs were isolated by Ficoll-Biocoll Separating Solution as the 
followings: 
 Cell culture medium (CTM): RPMI 1640 supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin 
 mixed 10 ml heparin blood 1:1 with 10 ml PBS in 50 ml tube 
 stacked above 5 ml of Ficoll-Biocoll separating solution 
 ２８ 
 centrifuge (1500 rpm, 30 min, 20°C , without brake) 
 picked up supernatant  
 isolated lymphocytes and the lymphocytes were resuspend in 20 ml     
sterile PBS  
 centrifuge (1500 rpm, 12 min, with brake) 
 discarded supernatant 
 repeated ‗resuspending in 20 ml sterile PBS, centrifuge and discarding 
supernatant‘ for two times 
 the lymphocytes were resuspended in 2ml CTM 
 under microscope, cell count was performed and the viability of cell was 
determined by trypan blue staining (which was always >95% in the formal 
experiments). The method for counting cell under microscope was as 
following: 
a  b 
   
c  d 
Cell number/ml = (a+b+c+d/4)×2×104 
2: cell suspension was diluted by trypan blue (1:1) 
104: 1.0mm (length)×1.0mm(width)×0.1mm(depth)=0.1mm3; 1ml=103 mm3 
 diluted the cell suspension with CTM. The final density is 2-3x 106 
cells/ml. 
4.4.2  LEV or VPA treatment 
 100µl of cell suspension was seeded at 2-3x 105 cells /well in 96-well                   
plates 
 96µl of CTM was added into each well 
  was added 4 µl of drugs or PBS 
o 4 µl of VPA dilution 2 (for end concentration of 100 mg/l) 
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o 4 µl of VPA dilution 3 (for end concentration of 10 mg/l) 
 - OR - 
o 4 µl of LEV dilution 2 (for end concentration of 50 mg/l) 
o 4 µl of LEV dilution 3 (for end concentration of 5 mg/l) 
AND 
o 4 µl of PBS to control samples 
 incubation for 1h or 24h at 37oC in a humidified, 5% CO2-air incubator 
4.4.3  Apoptosis evaluation with flow cytometer 
At the end of the culture under each condition, plates were centrifuged 
(1200rpm, 20 oC, 4 min, with brake) and supernatants were aspirated. Then, 
the cells were stained with CD3-APC and CD8- PerCP for 30 min in the 
dark on ice. Annexin V Apoptosis Detection Kit was used to detect 
apoptosis. Briefly, after washing with culture medium and centrifugation 
(1200rpm, 20 oC, 4 min, with brake), the cells were resuspended in 200µl of 
Annexin V binding buffer and incubated with 2µl of Annexin V-FITC and 2µl 
of PI for 10 min in the dark at room temperature. Then, apoptosis was 
measured on a four-colour flow cytometer (FACSCalibur®, CellQuest® 
software, Becton Dickinson). Data from at least 50 000 events per well 
were acquired. After gating lymphocyte characteristics using both forward 
and sideward scatter, apoptotic CD8+ T lymphocytes were defined as 
CD3+/CD8+/Annexin+/PI-. Spontaneous apoptosis was observed in cells 
untreated with LEV or VPA after incubation for 1 h and 24 h. 
 
 Annexin V and PI: In the current study, Annexin V and PI were used to 
distinguish between live, apoptotic and necrotic cells based on 
differences in membrane permeability.The hydrophilic protein Annexin 
V selectively binds to phosphatidylserine (PS), which was translocated 
from the inner face of the plasma membrane to the cell surface soon 
after initiating apoptosis (Koopman et al., 1994; van Engeland et al., 
1998). So, Annexin V staining can be used for distinguishing apoptotic 
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cells from their intact counterparts, but it can not distinguish apoptotic 
cells from necrotic cells because PS also exist on the surface of the 
latter. PI is impermeable to cells with an intact plasma membrane, and 
thus live and early apoptotic cells are not stained with PI (Darzynkiewicz 
et al., 1992; Vermes et al., 1995; Vermes et al., 2000). In late apoptotic 
and necrotic cells, nuclear membrane integrity was disrupted (Faleiro 
and Lazebnik, 2000; Kroemer et al., 1998). PI gains a access to the 
nucleus and intercalates into DNA, rendering the nucleus highly 
fluorescent (Darzynkiewicz et al., 1992; Vermes et al., 1995; Vermes et 
al., 2000). So, PI can be used for distinguishing early apoptotic cells 
from late apoptotic and necrotic cells. In the current study, apoptotic 
cells were defined as CD3+/CD8+/Annexin+/PI-. In fact, this definition 
was suitable for ealy apoptotic cells. 
4.5 Functional assay of virus-peptidess-specific CD8+ T lymphocytes 
4.5.1 Isolation of PBMCs  
PBMCs were isolated with Ficoll-Biocoll Separating Solution by density 
gradient centrifugation (1500rpm, 20 oC, 30 min, without brake) of 
heparinized blood  (20 ml) obtained by venepuncture of the heathy 
volunteers. PBMCs were isolated by Ficoll-Biocoll Separating Solution as 
described in 4.4.1 (final cell density : 2-3x 106 cells/ml). 
4.5.2 CEF peptides 
In the functional assays, CD8+ T lymphocytes were activated with 
CTL-CEF-Class I peptide pool ―Plus‖, which contained 32 peptides, each 
corresponding to a defined HLA class I restricted T-cell epitope from 
cytomegalovirus, Epstein-Barr virus and influenza virus. Most humans have 
been previously exposed to these pathogens. The fresh PBMCs were 
incubated with 64 µg/mL of CEF peptide at 37oC in a humidified, 5% CO2 
incubator for different time intervals. A negative control (without activation 
 ３１ 
by CEF peptide) was included in every experiment. 
 Working solution of CEF peptides (64 µg/mL) 
o Flicked tube to ensure that all powder was at the bottom of the tube.  
o Added 10μl tissue culture grade DMSO followed by 40µl of sterile  
double distilled water. Vortex briefly and watch sterile handling.  
o Stock solution: was added 450μl of tissue culture grade PBS and 
vortexed briefly. Flicked tube to ensure that all liquid was at the 
bottom of the tube.  
o Before use, added 500μl of stock solution into 4500μl CTM as the 
working solution (1:10) 
o The unused stock solution was stored at -20°C for less than 2 weeks. 
4.5.3 Perforin release 
Perforin release was measured as previously described with some 
modifications (Weren et al., 2004).  
 96µl of PBMCs suspension was seeded at 2-3x 105 cells /well in 96-well 
plates 
 was added 4 µl of drugs or PBS 
o 4 µl of VPA dilution 2 (for end concentration of 100 mg/l) 
o 4 µl of VPA dilution 3 (for end concentration of 10 mg/l) 
 - OR - 
o 4 µl of LEV dilution 2 (for end concentration of 50 mg/l) 
o 4 µl of LEV dilution 3 (for end concentration of 5 mg/l) 
AND 
o 4 µl of PBS to CEF-treated-control group 
o 4 µl of PBS to negative control group  
 incubation for 10 min (37oC； 5%CO2) 
 added 100 µl of working solution CEF peptides into AED-treated groups 
and CEF-treated-control group; added 100 µl of CTM in negative control 
group 
 incubation for 2h 37oC in a humidified, 5% CO2-air incubator 
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After activation of CD8+ T lymphocytes for 2 h in the presence or absence 
of antiepileptic drugs, the cells were first stained with CD3-APC and CD8- 
PerCP for 30 min and were then resuspended in BD Cytofix/Cytoperm 
solution for 20 min at 4°C. After washing and centrifugation (1200rpm, 20 
oC, 4 min, with brake), cells were labeled with perforin-PE or IgG-PE 
isotype control in Perm/Wash buffer solution. Then, perforin expression 
was measured via flow cytometry. Data from at least 50,000 events per well 
were acquired. The frequency of perforin expression was analyzed in the 
CD3+/CD8+ gate. The baseline of perforin expression was measured in 
unstimulated cells immediately after isolation.  
4.5.4 CD107 degranulation assay 
CD8+ T lymphocyte degranulation can be measured by increased 
expression of surface CD107a and CD107b (Betts et al., 2003; Betts et al., 
2004). CD107 expression was measured as previously described with 
some modifications (Betts et al., 2003). 
 added 216μl of CD107a/b-FITC into 480µl of PBMCs suspension (2-3x 
106 cells/ml)  
 added 116μl of PBMCs suspension mixed with CD107 into each cell 
 was added 4 µl of drugs or PBS  
o 4 µl of VPA dilution 2 (for end concentration of 100 mg/l) 
o 4 µl of VPA dilution 3 (for end concentration of 10 mg/l) 
 - OR - 
o 4 µl of LEV dilution 2 (for end concentration of 50 mg/l) 
o 4 µl of LEV dilution 3 (for end concentration of 5 mg/l) 
AND 
o 4 µl of PBS to CEF-treated-control group 
o 4 µl of PBS to negative control group   
 incubation for 10 min (37oC； 5%CO2) 
 added 80 µl of working solution CEF peptides into AED-treated groups 
and CEF-treated-control group; added 80 µl of CTM into negative 
control group  
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 incubation for 50min （37oC； 5%CO2） 
 was added 0.5 μl monesin (BD GolgiStop) 
 incubation for 1h 
After activation of CD8+ T lymphocytes for 2h in the presence or absence of 
antiepileptic drugs, the cells were stained with CD3-APC and CD8-PerCP 
for 30 min at 4°C in the dark. After washing, centrifuge and resuspending 
in 130μl of CTM, cells were analyzed on the four-colour flow cytometer. At 
least 50,000 events were collected per cell. The frequency of CD107a/b 
expression was analyzed in the CD3+/CD8+ gate. The baseline of 
CD107a/b expression was measured in unstimulated cells immediately 
after isolation. The cells were stained with CD107a/b-FITC, CD3-APC and 
CD8- PerCP at the same time. 
Monensen was used in this experiment because the expression of 
CD107a/b on the cell surface caused by degranulation is transient before 
those proteins are internalized (Fukuda, 1991). Monensin is a carboxylic 
ionophore specific for monovalent cations and can intercalate into 
membranes and exchange protons for potassium ions (Tartakoff, 1983; 
Mellman et al., 1986). Thereby, monensin can neutralize the pH within 
endosomes and lysosomes, which prevents degradation of fluorochrome 
conjugates of endocytosed anti-CD107 antibodies (Betts and Koup, 2004).  
4.5.5 Analysis of CD8+ T lymphocytes Proliferation by CFSE Labeling 
In 1994, Lyons and Parish set up the method that investigated the kinetics 
of lymphocyte proliferation with the fluorescein related dye CFSE and flow 
cytometry (Lyons and Parish, 1994). This approach has proved suitable for 
in vitro and in vivo study of T lymphocytes (Lyons and Parish, 1994; Kurts 
et al., 1997; Gett and Hodgkin, 1998). Its working principle was introduced 
by Lyons (Lyons, 2000.): CFSE consists of a fluorescein molecule 
containing two acetate moieties and a succinimidyl ester functional group. 
In this form, it is membrane permeant and non-fluorescent. After diffusion 
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into the intracellular environment, endogenous esterases remove the 
acetate groups, rendering the molecule highly fluorescent and 
non-permeant to the cell membrane. In addition, the succinimidyl ester 
reacts with free amine groups of intracellular proteins, forming dye–protein 
adducts. Proteins which have a low turnover rate, including some 
cytoskeletal components, are thought to be responsible for the very long 
lived staining afforded by CFSE. Importantly, cellular differentiation turned 
out to be unaffected by the dye CFSE (Hodgkin et al., 1996; Gett and 
Hodgkin, 1998). 
 
The protocol was as following: 
 preparation for working solution of IL2 
o 20mM AcOH：added 10µl of 100% AcOH into 8715µl sterile double 
distilled water 
o stock solution of IL2: added 10µg of IL2 into 100µl of 20mM AcOH. 
The concentration was 100µg/ml (1.3 x 106IU/ml) 
o aliquot stock solution of IL2 was stored at -20°C for less than 3 
weeks 
o when using, added 1µl of stock solution into 129µl of PBS，the latter 
concentration of IL2 was 10 000IU/ml. Then, added 0.8ul of 
10000IU/ml IL2 into 200µl CTM, the final working concentration of 
IL2 was about 40IU/ml 
 6ml PBMC-CTM : added 3ml CTM into 3ml of cell suspension (2-3x 106 
cells/ml) 
 CFSE preparation (CellTrace™ CFSE Cell Proliferation Kit): prepared a 
1.25 mM CellTrace™ CFSE stock solution immediately prior to use by 
dissolving the contents of one vial (Component A) in 72 μL of the DMSO 
provided (Component B). 
 added 1.9µl of CFSE stock solution into 6ml PBMC-CTM（the working 
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concentration of CFSE is 0.4µM） 
 incubation at 37oC for 10 min in the dark 
 the free CFSE was quenched with 30ml of ice-cold CTM for 5 min on ice 
 centrifuge for 4min,1500rpm 
 discarded supernatant 
 added 30ml of fresh CTM medium into the cells  
 centrifuge for 4min,1200rpm  
 discarded supernatant  
 repeated wash again 
 cells stained with CFSE were resuspended in 1ml of CTM  
 96µl of cell suspension (stained with CFSE) was seeded into 96-well 
plates 
 was added 4 µl of drugs or PBS 
o 4 µl of VPA dilution 2 (for end concentration of 100 mg/l) 
o 4 µl of VPA dilution 3 (for end concentration of 10 mg/l) 
 - OR - 
o 4 µl of LEV dilution 2 (for end concentration of 50 mg/l) 
o 4 µl of LEV dilution 3 (for end concentration of 5 mg/l) 
AND 
o 4 µl of PBS to CEF-treated-control group 
o 4 µl of PBS to negative control group  
 incubation for 10 min (37oC； 5%CO2) 
 added 100 µl of working solution CEF peptides into AED-treated groups 
and CEF-treated-control group; added 100 µl of CTM into negative 
control group 
 added 0.8ul of 10000IU/ml IL2 into AED-treated groups and 
CEF-treated-control group (the working concentration of IL2 was about 
40IU/ml) 
 incubation for 5d at 37oC in a humidified, 5% CO2-air incubator 
 
After the incubation, cells were washed with culture medium, next, cell 
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surface was stained with CD3-APC and CD8- PerCP as described above. 
Then, cells were analyzed on the four-colour flow cytometer. At least 
50,000 events were collected per cell. Cells proliferation was measured by 
the percantage of low CFSE cells in CD3+/CD8+ gate (in the upper left 
quadrant of each FACS plot). The definition for low CFSE cells was defined 
according to the distribution of CFSE dye in baseline, which was measured 
in unstimulated cells. CFSE decrease was a result of dye dilution in each 
cell division. Less than 1% CFSE dim (proliferating) cells were observed in 
the negative control groups. 
4.7 Statistical analysis  
All results are expressed as mean±standard deviations. Depending group 
comparisons were performed with the paired t-test. In this explorative study, the 
significance level was set to p<0.05.
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5  Results 
5.1 Apoptosis  
In the high-concentration VPA group (100 mg/L), the percentage of 
apoptotic CD8+ T lymphocytes was lower than in the control group after 24h 
of incubation (VPA 100mg/L vs control: 7.8±3.4% vs 11.5±4.2%, p<0.01, 
n=15, Table 2, Fig.3). Levetiracetam had no significant influence on 
apoptosis of CD8+ T lymphocytes after 1h or 24h. 
A representative example is shown in Fig. 4. 
 
 
Table 2: Comparative analysis for the percentage of spontaneous and drug-treated 
apoptosis in CD8
+
 T lymphocytes 
 
Incubation  
LEV  
(5 mg/l) 
LEV  
(50 mg/l) 
VPA  
(10 mg/l) 
VPA  
(100mg/l) 
Spontaneous 
1h 8.32±3.56 8.50±3.66 8.09±3.10 8.43±3.59 7.52±2.78 
24h 11.76±4.37 12.60±4.39 12.05±4.61 7.82±3.41
﹡﹡
 11.52±4.16 
﹡﹡p<0.01 (compared with spontaneous group, paired t-test) 
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Figure 3. 
Percentage of spontaneous (control) and drug-mediated (VPA 10mg/L, VPA 
100mg/L, LEV 5mg/L and LEV 50mg/L) apoptosis in CD8+ T lymphocytes (data 
given as mean ± SD (standard deviation)). Two asterisks indicate p<0.01 
comparing the control condition and the high dose VPA condition (n=15). 
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C:  The percentage of apoptosis in CD8+ T lymphocytes  
 
Figure 4.   
Flow cytometry analysis of spontaneous, VPA-treated and LEV-treated 
apoptosis of CD8+ T lymphocytes. These representative dot-plots are from a 
healthy volunteer‘s result. PBMCs were tested after 1h and 24h incubation. A: 
The lymphocytes region (R1) is shown in forward-scatter (FSC) versus 
side-scatter (SSC) dot plot. B: CD3 versus CD8 fluorescence dot plot shows 
CD8+ T lymphocytes region (R2) in lymphocytes gate (the R1 logical gate). C: 
Annexin V/FITC versus propidium iodide (PI) fluorescence dot plot shows the 
percentage of apoptosis in CD8+ T lymphocytes gate (the R1 AND R2 logical 
gate). Note decreased percentages of apoptotic cells (Annexin+/PI-) in high 
concentration (100mg/L) of VPA-treated group relative to other groups after 24h 
incubation.
A B 
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5.2 CEF-peptides-specific activation  
CEF-peptides-specific activation for CD8+ T lymphocytes was effectively 
induced in all volunteers. Perforin release, CD107a/b expression and 
proliferation were significantly increased in the CEF-peptides stimulated 
group as compared to control measurements after incubation for 2h and 
5days, respectively (control vs CEF : perforin+ cells 40.9±10.9% vs 18.2±
9.7%, p<0.01; CD107+ cells 0.7±0.4% vs 11.5±4.7%, p<0.01; low CFSE 
cells 1.0±0.4% vs 6.9±2.9%, p<0.01; n=15, Fig. 5). In addition, after 2h 
measurements, there was a small, but significant drop in perforin+ cells and 
increase of CD107+ cells in the control group as compared to baseline 
indicating little degranulation of CD8+ T lymphocytes in vitro culture (control 
vs baseline : perforin+ cells 40.9±10.9% vs 47.0±12.3%, p<0.05; CD107+ 
cells 0.7±0.4% vs 0.5±0.2%, p<0.05; n=15, Fig. 5). 
 
 
 
Figure 5. 
Percentage of perforin+, CD107+ and low CFSE CD8+ T lymphocytes at baseline, 
under control condition and after CEF-stimulatation. No LEV or VPA was added.  
(data given as mean ± SD (standard deviation); one asterisk: p<0.05; two 
asterisks: p<0.01).  
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5.3 Perforin release 
Both high and low concentration of LEV decreased perforin release in CD8+ 
T lymphocytes after CEF-peptide stimulation of 2 h (LEV 50 mg/L vs CEF : 
25.8±12.9% vs 18.2±9.7%, p<0.01; LEV 5mg/L vs CEF: 24.1±13.7% vs 
18.2±9.7%, p<0.01; n=15, Table3, Fig. 6). Adding valproate in a low or 
high concentration did not change perforin release (p>0.05; Table3, Fig. 6)  
A representative example is shown in Fig. 7. 
 
Table 3: Comparative analysis of perforin
+
 cells, CD107
+
 cells and CFSE low cells in 
the CEF-stimulated group versus CEF-drug-treated groups 
 
 
CEF-LEV  
(50mg/l) 
CEF-LEV  
(5 mg/l) 
CEF-VPA  
(100 mg/l) 
CEF-VPA  
(10mg/l) 
CEF 
2h 
perforin
+
 
25.8±12.9﹡﹡ 24.1±13.7﹡﹡ 19.0±11.9 20.3±13.0 18.2±9.7 
2h CD107
+
 5.3±2.5
﹡﹡
 6.7±2.2﹡﹡ 11.0±5.5 10.9±5.0 11.5±4.7 
5d CFSE 
low 
6.9±3.4 6.6±3.1 7.0±3.5 6.8±3.0 6.9±2.9 
﹡﹡p<0.01 (compared with CEF group, paired t-test). 
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Figure 6. 
Perforin+, CD107+ and low CFSE CD8+ T lymphocytes in the CEF-stimulated 
group and in CEF-stimulated groups in the presence of LEV or VPA at different 
concentrations, including VPA 10mg/L, VPA 100mg/L, LEV 5mg/L and LEV 
50mg/L. (Data given as mean ± SD (standard deviation); two asterisks: p<0.01). 
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Figure 7. 
Representative examples of histograms analysis of perforin release in CD8+ T 
lymphocytes gate. Lymphocytes gate and CD8+ T lymphocytes gate were 
defined as described above. Due to the unimodal distribution of perfoin, the mark 
for perforin+ cells was set up on the middle point of the baseline distribution. 
PBMCs were stimulated by CEF peptide for 2h in the presence or absence of 
antiepileptic drugs. Perforin release was observed by comparing the the 
percentage of perforin+ cells in baseline group with that in the control group or 
CEF-stimulated group (including CEF, LEV 5mg/L, LEV 50mg/L, VPA 10mg/L 
and VPA 100mg/L). Note higher percentage of perforin+ cells in LEV-treated 
group (5mg/L and 50mg/L) relative to other CEF-stimulated groups (CEF, VPA 
10mg/L and VPA 100mg/L).  
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5.4 CD107a/b expression 
After 2h of stimuation, both high (50mg/L) and low (5mg/L) concentrations 
of LEV decreased CD107a/b expression on CD8+ T lymphocytes compared 
with the CEF-peptides stimulated group (LEV 50mg/L vs controls: 5.3±
2.5% vs 11.5±4.7%, p<0.01; LEV 5mg/L vs controls: 6.7±2.2% vs 11.5±
4.7%, p<0.01; n=15, Table3, Fig. 6). CD107 expression on cell surface and 
perforin release are two important methods for degranulation assay (Betts 
et al., 2003; Betts et al., 2004; Weren et al., 2004). Moreover, CD107a/b 
expression was concomitant with a loss of perforin (Betts et al., 2003). In 
our study, both data from CD107a/b expression experiments and data from 
perforin release experiments drawed a same conclusion that LEV 
decreases degranulation of CD8+ T lymphocytes induced by CEF-peptide 
stimulation in vitro. 
Valproate did not reveal a significant effect on CD107a/b expression. 
A representative example of LEV decreasing the CD107a/b expression is 
shown in Fig. 8. 
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Figure 8. 
Degranulation analysis of CD8+ T lymphocytes were performed with cell surface 
CD107a/b expression. In this representative example, lymphocytes gate and 
CD8+ T lymphocytes gate were defined as described above. PBMCs were 
stimulated by CEF peptide for 2h in the presence or absence of antiepileptic 
drugs. Degranulation was observed by comparing the the percentage of 
CD107a/b+ cells in baseline group with that in the control group or 
CEF-stimulated group (including CEF, LEV 5mg/L, LEV 50mg/L, VPA 10mg/L 
and VPA 100mg/L). After 2h incubtion, LEV-treated group (5mg/L and 50mg/L) 
showed lower percentages of CD107a/b+ cells than other CEF-stimulated 
groups (CEF, VPA 10mg/L and VPA 100mg/L).  
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5.5 Proliferation 
Levetiracetam and VPA did not influence proliferation of CD8+ T 
lymphocytes induced by CEF-peptide stimulation (p>0.05, n=15, Table3, 
Fig. 6).  
A representative example of proliferation of CD8+ T lymphocytes induced 
by CEF-peptides-stimulation is shown in Fig. 9. 
 
 
Figure 9. 
In this representative example, lymphocytes gate and CD8+ T lymphocytes gate 
were defined as described above. Proliferation of CD8+ T lymphocytes was 
measured in the upper left quadrant of each FACS plot, which reflected CFSE 
dilution. No obvious difference was found between CEF-peptides-stimulated 
group and CEF-drug-treated groups. 
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6  Discussion 
The main finding of this study was that LEV had a attenuating effect on 
degranulation of CD8+ T lymphocytes as indicated by reduced perforin 
release and decreased CD107a/b expression after CEF-peptide stimulation 
in vitro. Levetiracetam did not appear to influence apoptosis or proliferation 
of CD8+ T lymphocytes. In contrast, high concentrations of VPA prevented 
spontaneous apoptosis of CD8+ T lymphocytes in vitro but did not have any 
effects on proliferation or perforin release.  
6.1 Methodology  
Because CD8+ T lymphocytes play a key role in immune surveillance for 
eliminating of virus infected cells, certain tumor cells, and MHC class I 
incompatible cells (Hussell et al., 1997; Trapani and Smyth, 2002; 
Lieberman, 2003), many different types of cytotoxicity assay have been 
developed. These methods can be divided into groups: the first group lays 
particular emphasis on measuring target cell death and the second focus 
on observing the cytotoxic pathways. The former includes the 51chromium 
release assay (Pearson et al., 1969), the detection of DNA-degradation 
(Brawn et al., 1975) and the release of fluorescent dyes such as 
bis-carboxyethyl-carboxyfluorescein (Kolber et al., 1988). These 
techniques are cumbersome, semi-quantitative, and potentially insensitive 
(Betts et al., 2003). More recently, many new methods based on flow 
cytometry have been established to observe intracellular cytokine 
production, CFSE-based proliferation and degranulation (Brenchley et al., 
2002; Betts et al., 2003; Weren et al., 2004). This second group of tests 
directly examines the functional state of CD8+ T lymphocytes rather than 
the death of target cells. These assays are often simple, rapid and sensitive. 
Therefore, we chosed the second this method for the current study.  
As described in the introduction, degranulation-dependent mechanism is 
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principal compared with granule-independent pathway. So, in the current 
study, degranulation was taken as the main marker of cytotoxicity of 
virus-peptides-specific CD8+ T lymphocytes. Degranulation assay can be 
performed with at least two classical kinds of methods: perforin release and 
the increase of CD107 expression on cell surface (Betts et al., 2003; Betts 
et al., 2004; Weren et al., 2004).  
Perforin is a key component of the lytic granules machinery in cytotoxic 
CD8+ T lymphocytes and perforin release plays a critical role in 
cell-mediated cytotoxicity against viral infection (Barry and Bleackley, 2002; 
Russell and Ley, 2002; Lieberman, 2003). In the previous studies, 
granule-mediated killing occured within minutes to hours of target cell 
recognition. The following reconstitution or upregulation of intracellular 
perforin could not be detected until cellular proliferation (Sandberg et al., 
2001; Migueles et al., 2002; Meng et al., 2006). However, Hersperger et al. 
recently found that antigen-specific CD8 T lymphocytes rapidly upregulate 
perforin after activation for 6h if B-D48 clone anti-perforin antibody, but not 
δ G9 clone antibody, was employed (Hersperger et al., 2008). In the 
current study, we used δ G9 clone anti-perforin antibody and perforin was 
detected after CEF-peptides-stimulation of 2h. So, the intracellular perforin 
reduction only reflected perforin release. In baseline, perforin had the 
unimodal distribution. So, the mark for perforin+ cells was set up on the 
middle point of the baseline distribution in most cases, which is consistent 
with some previous studies (Appay et al., 2000; Zhang et al. 2003; Harari et 
al., 2009). 
There is a difference in staining methods between intracellular perforin 
staining and cell surface staining of CD107. Intracellular perforin staining 
needs cell fixation and permeabilization, which possibly incerease perforin 
loss and degranulation. The fixation and permeabilization are unnecessary 
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for cell surface staining of CD107. So, perforin staining possibly showed 
more obvious degranulation than cell surface staining of CD107, which was 
once reported in the previous study (Weren et al., 2004). In our study, the 
potential discrepancy caused by methodology did not result in the 
inconsistent conclusion. Both data from CD107a/b expression experiments 
and data from perforin release experiments led to the same conclusion that 
LEV decreases degranulation of CD8+ T lymphocytes induced by 
CEF-peptide stimulation in vitro.  
6.2 Degranulation and anti-virus function  
In clinical studies, LEV treatment increased the incidence of common cold, 
pharyngitis and rhinitis which was associated with a slight but significant 
drop in white blood cell counts (Harden, 2001). Similarly, a study on 
interictal alterations of leukocytes and cytokines in the blood of patients 
with active epilepsy found a trend towards decreased counts of CD8+ T 
lymphocytes (Nowak et al, 2010). 
It is well known that CD8+ T lymphocytes play a central role in the defense 
against viral infections, especially for the clearance of virus (Lukacher and 
Wilson, 1998; Thimme et al., 2003; Mosley et al., 2005 ). However, there 
was once a debate regarding the immediate cytotoxic function of CD8+ T 
lymphocytes (McMichael et al., 1986; Lau et al., 1994; Bachmann et 
al.,1999). Recently, the immediate induction for cytotoxic function, involving 
cell cloning and lysis of target cells, was reported in human 
influenza-specific CD8+ T lymphocytes (Touvrey et al., 2009), which was 
greater than previously described in mice (Selin and Welsh, 1997; Kedl and 
Mescher, 1998). Moreover, CD8+ T lymphocytes was also found to play a 
role in innate immunity (Berg and Forman, 2006). Our results support the 
existence of immediate cytotoxic function of CD8+ T lymphocytes, which 
was shown by degranulation and perforin release. So, CD8+ T lymphocytes 
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is not only crucial for the clearance of virus, but also plays an important role 
for preventing virus infection. 
Although this study did not confirm a significant effect of LEV on apoptosis 
of CD8+ T lymphocytes in vitro, the results provided clear evidence that 
levetiracetam compromised the function of CD8+ T lymphocytes. 
Cytotoxicity of CD8+ T lymphocytes is mainly mediated by release of 
pre-formed cytolytic granules which contain perforin, other less important 
pathways involve the secretion of soluble cytokines and Fas/FasL 
interaction (Walker et al., 1986; Walker et al., 1987; Barry and Bleackley, 
2002; van Lier et al., 2003; Kaech et al., 2007). The major function of 
perforin is to insert into the target membrane and to form pores of about 16 
nm in diameter by polymerization in order tofacilitate the entry of granzyme 
which leads to DNA fragmentation (Young et al., 1986; Liu et al., 1995). 
Mice deficient in perforin were severely immunocompromised, and so were 
humans with familial hemophagocytic lymphohistiocytosis (HLH) due to 
mutations of the perforin gene (Kagi et al., 1994). Degranulation leading to 
perforin release is the key process of cytotoxic function of CD8+ T 
lymphocytes (Barry and Bleackley, 2002; Russell and Ley, 2002; Lieberman, 
2003). The cytotoxic granule of CD8+ T lymphocytes are membrane-bound 
secretory lysosomes that contain a dense core composed of various 
proteins, including perforin and granzymes (Peters et al., 1991). The core is 
surrounded by a lipid bilayer containing lysosomal associated membrane 
glycoproteins (LAMPs), including CD107a (LAMP-1), CD107b (LAMP-2), 
and others (Peters et al., 1991). Degranulation can cause positive 
expression of CD107a/b on the cell surface for a brief period of time before 
these proteins are internalized (Fukuda, 1991). So, the expressions of 
CD107 on the CD8+ T lymphocytes can become a marker for degranulation. 
The attenuating effect of LEV on perforin release and degranulation may 
contribute to the higher infection rates in LEV-treated patients. The exact 
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time course of the interaction of LEV and cytotoxicity of CD8+ T 
lymphocytes in vivo remains to be established. 
6.3 Perforin release and antiepileptic mechanism  
A series of studies have supported the view that transient openings of the 
blood-brain-barrier (BBB) facilitate both behavioral and electrographic 
seizures and may establish a link between the systemic immune system 
and the epileptogenic zone (Van Vliet et al., 2007; Marchi et al., 2007; 
Kleen and Holmes, 2008). Disruption of BBB permeability is a possible 
pathway for cytokines influencing seizures and epilepsy. Several studies 
revealed BBB ‗failure‘ after administration of IL-1, IL-6, TNFα, and 
interferon-γ (De Vries et al., 1996; Wong et al., 2004; Candelario-Jalil et al., 
2007). In a mouse model of epilepsy induced by pilocarpine, Fabene et al., 
found that leukocyte-endothelial interactions were altered by seizures and 
played an important role in BBB damage and seizure generation (Fabene 
et al, 2008). 
Recently, it was reported that CD8+ T lymphocytes can lead to BBB 
dysfunction through a perforin-dependent process (Suidan et al., 2010). 
Similarly, Kim et al. observed a reduction of CNS vascular permeability in 
perforin-deficient-mice infected with lymphocytic choriomeningitis virus 
(Kim et al., 2009). Therefore, perforin also plays a role in BBB permeability. 
It may be hypothesized that LEV‘s attenuating effect on perforin release 
may add to its anticonvulsant potency via reduction of BBB disruption. 
6.4 Apoptosis and proliferation  
This study did not reveal any effects of LEV on apoptosis and proliferation 
of CD8+ T lymphocytes, which refused our initial hypothesis that LEV could 
decrease the amount of CD8+ T lymphocytes.  
We also found that VPA had neither influence on proliferation of CD8+ T 
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lymphocytes nor influence on degranulation of CD8+ T lymphocytes. 
However, 100mg/L of VPA reduced spontaneous apoptosis of CD8+ T 
lymphocytes in healthy volunteers. Similarly, it was previously reported that 
healthy donor CD3+ T cells were significantly less sensitive to apoptosis 
induction by VPA than primary chronic lymphocytic leukemia cells 
(Bokelmann and Mahlknecht, 2008). This insensitivity was more prominent 
for high concentrations (3 mM) of VPA than low concentration (0.1 and 1 
mM), although the antiapoptotic effect of VPA was not overemphasized by 
the authors. Moreover, a few studies indicated the antiapoptotic effect of 
VPA and other HDAC inhibitors on ischemic neurons and non-small cell 
lung cancer cells (Mayo et al., 2003; Chuang, 2005). In contrast to the 
antiapoptotic effects, more evidence from in vitro culture, animal model 
studies and clinical observations has shown that VPA can render various 
cancer cells more susceptible to apoptosis by HDAC inhibition, reactive 
oxygen species production, DNA damage, caspase-dependent pathway 
and other mechanisms (Kawagoe et al., 2002; Chen et al., 2006; 
Bokelmann and Mahlknecht, 2008; Lin et al, 2008; Ozaki et al, 2008). 
Therefore, these results support the view that VPA has anti- as well as 
proapoptotic effects depending on the target cell type . It is less clear for the 
current study whether these effects of VPA contribute to its anticonvulsant 
or adverse effects. 
6.5 The preliminary observation for SV2A expression in human CD8+ T 
lymphocytes 
The main finding of this study was that LEV had a attenuating effect on 
degranulation of CD8+ T lymphocytes. For disclosing the mechanism of this 
depressive effect, it was hypothesized for from our experiments that SV2A, 
the binding site of LEV, exist in human CD8+ T lymphocytes. 
Synaptic vesicle protein 2 (SV2) is a highly glycosylated protein involved in 
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exocytosis (Buckley and Kelly, 1985; Portela-Gomes et al., 2000). 
Vertebrates have three distinct genes encoding highly homologous proteins 
referred to as SV2A, -B and -C isoforms (Bajjalieh et al., 1992; Bajjalieh et 
al., 1993; Feany et al., 1992). SV2A is the most widely distributed isoform, 
being nearly in all types of neurons, as well as being present in endocrine 
cells (Buckley and Kelly,1985; Bajjalieh et al., 1993; Bajjalieh et al., 1994; 
Xu and Bajjalieh, 2001). SV2A knockout mice fail to grow, develop severe 
seizures and die within the first weeks of life, – a phenotype that suggests 
both neurological and endocrine deficits (Crowder et al., 1999; Janz et al., 
1999). In neurons, SV2A is associated with synaptic vesicle fusion, 
exocytosis, and neurotransmitter release (Crowder et al., 1999). SV2A was 
identified as the binding site of LEV in the brain (Lynch et al., 2004). The 
specific effect of LEV binding to SV2A appears to be a reduction in the rate 
of vesicle release (Yang et al 2007). In adrenal chromaffin cells, SV2A is 
associated with calcium-dependent exocytotic burst (Xu and Bajjalieh, 
2001).  
To test the above mentioned hypothesis that SV2A is also involved in the 
degranulation, we preliminarily observed measured SV2A expression in 
human CD8+ T lymphocytes in one healthy person:. The freshly isolated 
PBMCs were first stained with CD3-APC, CD8- PerCP for 30 min. Then, 
the stained PBMCs were resuspended in BD Cytofix/Cytoperm® solution 
for 20 min at 4°C. After washing and centrifugation (1200rpm, 20 oC, 4 min, 
with brake), PBMCs were labeled with SV2A-FITC (GmbH, Aachen, 
Germany) in Perm/Wash buffer solution. IgG isotype control (FITC) was 
used for negative control. Then, SV2A expression was measured via flow 
cytometry. Our The preliminary results showed that iSV2A was probably 
likely to be expressed in human CD8+ T lymphocytes. A representative 
example is shown in Fig. 10. Therefore, SV2A inhibition possibly explains 
the depressive effects of LEV on degranulation of CD8+ T lymphocytes. 
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More work is being currently performed to verify this conclusion.  
 
Figure 10. 
In this representative example, lymphocytes gate and CD8+ T lymphocytes 
gate were defined as described above. The histogram of SV2A-FITC and 
IgG isotype control (FITC) were overlapped. 
 
6.6 Limitations 
A limitation of this study was that CD8+ T lymphocytes were taken from 
healthy volunteers and not from epilepsy patients. Alterations in immune 
cells and cytokine expression have been observed both in human epileptic 
patients and in animal models of epilepsy (Plata-Salamán et al., 2000; 
Ravizza and Vezzani 2006; Lehtimäki et al., 2007; Bauer et al., 2008, 2009). 
A study to confirm the present results in epilepsy patients is, therefore, 
underway. 
6.7 Conclusion  
Taken together, our studies found that LEV had moderate depressive effect 
on degranulation of CD8+ T lymphocytes, indicating that LEV can disturb 
the anti-virus function of immune system. This effect is likely to explain the 
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increased incidence of infection in LEV-treated patients with epilepsy, and 
also shed light on a new antiepileptic mechanism of LEV in the sense of 
reduction of BBB disruption caused by perforin release. There is a great 
need for further studies to verify these conclusions in future studing 
epileptic patients in vivo or animal models. 
 
. 
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